Latest & greatest articles for hydralazine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydralazine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydralazine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydralazine

1. Comparison of efficacy and safety of labetalol and hydralazine in hypertension in pregnancy: a systematic review and meta-analysis

Comparison of efficacy and safety of labetalol and hydralazine in hypertension in pregnancy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

2. Hydralazine

Hydralazine Top results for hydralazine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydralazine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial

Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial There is a paucity of good quality evidence regarding the best therapeutic option for acute control of blood pressure during acute hypertensive emergency of pregnancy.We sought to compare the efficacy of intravenously administered hydralazine and oral nifedipine for acute blood pressure control in acute hypertensive emergency of pregnancy.In this double-blind, randomized, controlled trial (...) , pregnant women (≥24 weeks period of gestation) with sustained increase in systolic blood pressure of ≥160 mm Hg or diastolic blood pressure of ≥110 mm Hg were randomized to receive intravenous hydralazine injection in doses of 5, 10, 10, and 10 mg and a placebo tablet or oral nifedipine (10 mg tablet up to 4 doses) and intravenous saline injection every 20 minutes until the target blood pressure of 150 mm Hg systolic and ≤100 mm Hg diastolic was achieved. Crossover treatment was administered

2018 EvidenceUpdates

4. Outcomes of hydralazine induced renal vasculitis (PubMed)

Outcomes of hydralazine induced renal vasculitis Hydralazine has been implicated as an etiologic agent for lupus-like syndrome and vasculitis. Hydralazine-induced vasculitis frequently affects the kidney, but the long-term renal outcomes in these patients have not yet been studied.Patients who had a diagnosis of ANCA-associated vasculitis (AAV) and were on hydralazine at the time of AAV diagnosis were included in this retrospective cohort study. Clinical and laboratory data were obtained from (...) the review of medical records.Seven patients met the criteria for hydralazine-induced AAV. Five patients (71%) were African-American and four (57%) were female. The median age was 69 years at the time of diagnosis. All patients had renal involvement with two of them showing lung involvement as well. All patients had positive MPO antibody and one patient had positive PR3 antibody. ANA was positive in all patients, and three of seven patients had positive anti-histone antibody. All of them were treated

Full Text available with Trip Pro

2017 European journal of rheumatology

5. Hydralazine in infants with persistent hypoxemic respiratory failure. (PubMed)

Hydralazine in infants with persistent hypoxemic respiratory failure. Most deaths of infants with chronic lung disease (CLD) are caused by respiratory failure, unremitting pulmonary artery hypertension (PAH) with cor pulmonale, or infection. Although the exact prevalence of PAH in infants with CLD is unknown, infants with CLD and severe PAH have a high mortality rate. Except for oxygen supplementation, no specific interventions have been established as effective in the treatment for PAH (...) in premature infants with CLD. Little has been proven regarding the clinical efficacy of vasodilators and concerns remain regarding adverse effects.To review current evidence for the benefits and harms of hydralazine therapy to infants with persistent hypoxemic respiratory failure.We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE via PubMed and EMBASE, and other clinical trials registries through November 2011 using the standard search strategy

2013 Cochrane

6. Hydralazine for essential hypertension. (PubMed)

Hydralazine for essential hypertension. Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine is still widely used in developing countries due to its lower cost. A review of its relative (...) effectiveness compared to placebo on surrogate and clinical outcomes is justified.To quantify the effect of hydralazine compared to placebo in randomized controlled trials (RCTs) on all cause mortality, cardiovascular mortality, serious adverse events, myocardial infarctions, strokes, withdrawals due to adverse effects and blood pressure in patients with primary hypertension.We searched the following databases: Cochrane Central Register of Controlled Trials (2011, Issue 3), MEDLINE (1948-August 2011

2011 Cochrane

7. Hydralazine for essential hypertension. (PubMed)

Hydralazine for essential hypertension. Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine is still widely used in developing countries due to its lower cost. A review of its relative (...) effectiveness compared to placebo on surrogate and clinical outcomes is justified.To quantify the effect of hydralazine compared to placebo in randomized controlled trials (RCTs) on all cause mortality, cardiovascular mortality, serious adverse events, myocardial infarctions, strokes, withdrawals due to adverse effects and blood pressure in patients with primary hypertension.We searched the following databases: Cochrane Central Register of Controlled Trials (to Second Quarter 2009), MEDLINE (2005-June 2009

2010 Cochrane

8. Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patie

Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patie Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients Article Text Therapeutics Isosorbide dinitrate plus hydralazine was effective for advanced heart failure

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

9. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. (PubMed)

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy.A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus (...) hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life.The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better

2004 NEJM

10. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. (PubMed)

Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. To review outcomes in randomised controlled trials comparing hydralazine against other antihypertensives for severe hypertension in pregnancy.Meta-analysis of randomised controlled trials (published between 1966 and September 2002) of short acting antihypertensives for severe hypertension in pregnancy. Independent data abstraction by two reviewers. Data were entered into RevMan software for analysis (fixed effects (...) model, relative risk and 95% confidence interval); in a secondary analysis, risk difference was also calculated.Of 21 trials (893 women), eight compared hydralazine with nifedipine and five with labetalol. Hydralazine was associated with a trend towards less persistent severe hypertension than labetalol (relative risk 0.29 (95% confidence interval 0.08 to 1.04); two trials), but more severe hypertension than nifedipine or isradipine (1.41 (0.95 to 2.09); four trials); there was significant

Full Text available with Trip Pro

2003 BMJ

11. THE EVALUATION OF ANTIHYPERTENSIVE THERAPY COOPERATIVE CLINICAL TRIAL METHOD. I. DOUBLE-BLIND CONTROL COMPARISON OF CHLOROTHIAZIDE, RAUWOLFIA SERPENTINA, AND HYDRALAZINE. (PubMed)

THE EVALUATION OF ANTIHYPERTENSIVE THERAPY COOPERATIVE CLINICAL TRIAL METHOD. I. DOUBLE-BLIND CONTROL COMPARISON OF CHLOROTHIAZIDE, RAUWOLFIA SERPENTINA, AND HYDRALAZINE. 14233806 1996 12 01 2018 12 01 0003-4819 61 1964 Nov Annals of internal medicine Ann. Intern. Med. THE EVALUATION OF ANTIHYPERTENSIVE THERAPY COOPERATIVE CLINICAL TRIAL METHOD. I. DOUBLE-BLIND CONTROL COMPARISON OF CHLOROTHIAZIDE, RAUWOLFIA SERPENTINA, AND HYDRALAZINE. 829-46 SMITH W M WM DAMATO A N AN GALLUZZI N J NJ GARFIELD (...) C F CF HANOWELL E G EG STIMSON W H WH THURM R H RH WALSH J J JJ BROMER L L eng Journal Article United States Ann Intern Med 0372351 0003-4819 0 Antihypertensive Agents 0 Placebos 26NAK24LS8 Hydralazine 77W477J15H Chlorothiazide OM Antihypertensive Agents Biomedical Research Chlorothiazide Double-Blind Method Drug Therapy Heart Diseases Humans Hydralazine Hypertension Pharmacology Placebos Rauwolfia CHLOROTHIAZIDE CLINICAL RESEARCH DRUG THERAPY HEART DISEASES HYDRALAZINE HYPERTENSION PHARMACOLOGY

1996 Annals of Internal Medicine

12. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. (PubMed)

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg (...) of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial.Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm

1991 NEJM